SyMRI 3D reportedly combines precise estimates of regional brain volume with improved resolution bolstering accuracy with lesion analysis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for SyMRI 3D, a modality that may offer enhanced resolution and accuracy for brain magnetic resonance imaging (MRI) scans.
Combining quantitative MRI technology with isotropic resolution, SyMRI 3D provides improved accuracy in brain lesion analysis and facilitates brain structure and function assessments through precise brain region volume estimates, according to SyntheticMR U.S., the developer of the SyMRI 3D modality.
The newly FDA-cleared SyMRI 3D reportedly provides improved resolution that enhances accuracy of brain lesion analysis and better precision of brain region volume estimates, according to SyntheticMR U.S., the developer of the modality. (Image courtesy of SyntheticMR U.S.)
“Receiving 510(k) clearance for SyMRI 3D allows us to empower physicians to make more precise and informed decisions in diagnosis and treatment planning through quantitative imaging," said Jared Dixon, the president of SyntheticMR U.S.
SyMRI 3D will also be available to Philips customers as per a recently expanded partnership agreement between the two companies that was announced in November 2023.
Study: Abbreviated Breast MRI Offers Equivalent Accuracy to mpMRI for Women with Dense Breasts
May 20th 2025Emerging research suggests that abbreviated breast MRI offers comparable sensitivity and specificity as multiparametric MRI in women with extremely dense breasts with a nearly 50 percent reduction in reading time for radiologists.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.